RPTX

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
69
Score
7 Buy (78%)2 Hold (22%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
778%
Hold
222%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$3.00
+13.2%
Consensus
$15.00
+466.0%
Bull
$30.00
+1032.1%
12-Month Target Range9 analysts
$3.00$15.00$30.00
Current $2.65Consensus
Current Price
$2.65
Upside to Consensus
$12.35

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+41.10%
EPS
FY2028
Rev+59.46%
EPS
FY2029
Rev+833.33%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$7M$9M$15M$140M
Low$7M$9M$15M$140M
High$7M$9M$15M$140M
EBITDA Avg$-52M$-24M$-23M$-19M
Low$-52M$-24M$-23M$-19M
High$-52M$-24M$-23M$-19M
EBIT Avg$-53M$-25M$-25M$-28M
Low$-53M$-25M$-25M$-28M
High$-53M$-25M$-25M$-28M
Net Income Avg$-53M$-25M$-25M$-28M
Low$-53M$-25M$-25M$-28M
High$-53M$-25M$-25M$-28M
EPS Avg$-1.26$-0.60$-0.60$-0.65
Low$-1.26$-0.60$-0.60$-0.65
High$-1.26$-0.60$-0.60$-0.65
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$3M$3M
Low$3M$3M
High$3M$3M
EBITDA Avg$-14M$-14M
Low$-14M$-14M
High$-14M$-14M
EBIT Avg$-14M$-14M
Low$-14M$-14M
High$-14M$-14M
Net Income Avg$-14M$-14M
Low$-14M$-14M
High$-14M$-14M
EPS Avg$-0.32$-0.32
Low$-0.32$-0.32
High$-0.32$-0.32
Analysts (Rev / EPS)1 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Oct 27, 2025H.C. Wainwright
Repare Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
Target:$3.00
+63.5%from $1.83
Sep 4, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Repare Therapeutics (RPTX)
Target:$10.00
+255.9%from $2.81
Feb 3, 2023Morgan Stanley
Morgan Stanley Downgrades Repare Therapeutics to Equal-Weight, Lowers Price Target to $15
Target:$15.00
+14.2%from $13.14
Nov 17, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $25
Target:$25.00
+47.1%from $17.00
Jun 20, 2022Piper Sandler
Repare Therapeutics (RPTX) Stock: $30 Target And Overweight Rating
Target:$30.00
+126.1%from $13.27
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.